This section has information on Special Patient Populations. Please click on the below links or follow the table of contents to access the information you are looking for. Women with HIV Substance Use Disorders and HIV HIV-2 Infection Early (Acute and Recent) HIV Infection Transgender People with HIV HIV and the Older Person Adolescents and …
AU Comment: Ibalizumab (IBA) Ibalizumab (IBA) a monoclonal antibody that is NOT PBS listed in Australia. Discontinuation or interruption of antiretroviral therapy (ART) may result in viral rebound, immune decompensation, and/or clinical progression.1-5 Thus, discontinuation or planned interruption of ART is not recommended outside the context of a clinical trial (AI). However, unplanned interruption of ART may …
Panel’s Recommendations for Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression Key Considerations and Panel’s Recommendations A long-acting ARV regimen of injectable cabotegravir (CAB) and rilpivirine (RPV) given every 1 or 2 months is an optimization option for patients who are engaged with their health care, virologically suppressed on oral therapy for 3 to …
Optimising ART in the Setting of Virologic Suppression Read More »
AU Comment: Poor CD4 cell recovery and persistent inflammation despite viral suppression Current DHHS recommendations are suitable for implementation in Australia, including the following points: In individuals with viral suppression, adding ARV drugs or switching ARV drug classes does not consistently improve CD4 cell recovery or reduce all relevant markers of immune activation and is not …
AU Comment: Australian Special Access Scheme for ARV treatments In heavily treatment-experienced patients, where treatment options are limited by drug resistance, toxicities or other issues, enrolment in a clinical trial of a new antiretroviral agent (if available), or use of an agent not yet TGA-approved for marketing but available through the Special Access Scheme, can …
This section has information on Management of the Treatment-Experienced Patient. Please click on the below links or follow the table of contents to access the information you are looking for. Virologic Failure Optimizing ART in the Setting of Virologic Suppression Poor CD4 Cell Recovery Discontinuation or Interruption of ARV
AU Comment: Doravirine and Atazanavir/Ritonavir Australian clinicians should note that neither Atazanavirc o–formulated with ritonavir nor Doravirine are listed on the PBS. Note: All drugs within an ARV class are listed in alphabetical order.
Sub-section: Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal Most currently recommended antiretroviral (ARV) regimens consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third active drug. In some clinical situations, it is preferable to avoid abacavir (ABC), tenofovir alafenamide (TAF), …
Sub-section: Protease Inhibitor-Based Regimens Summary The Food and Drug Administration (FDA)-approved protease inhibitors (PIs) include atazanavir (ATV), ATV/cobicistat (ATV/c), darunavir (DRV), darunavir/cobicistat (DRV/c), fosamprenavir (FPV), indinavir (IDV), lopinavir/ritonavir (LPV/r), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and tipranavir (TPV). PI-based regimens using pharmacokinetic (PK) enhancement with either cobicistat (COBI) or RTV (also called PK boosting) increase …
The ARV Guidelines with Australian commentary is administered by ASHM
The Australian Government Department of Health
Prescribers
Contact Us
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2022 ASHM